search
Back to results

Evaluation of Systane Complete for the Treatment of Contact Lens Discomfort

Primary Purpose

Contact Lens Discomfort, Dry Eye

Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Systane Complete
Sponsored by
University of Alabama at Birmingham
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Contact Lens Discomfort focused on measuring Artificial Tears, Systane Complete, Contact Lens Discomfort, Dry Eye, Daily Disposable Contact Lenses

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Self-reported contact lens discomfort
  • Contact Lens Dry Eye Questionnaire (CLDEQ)-8 scores ≥ 12
  • Daily disposable contact lens wearer
  • Best-corrected visual acuity of 20/30 or better

Exclusion Criteria:

  • All other contact lens types (e.g., currently wearing two week or monthly replacement contact lenses or hard contact lenses)
  • Non-compliant daily disposable contact lens wearers (must regularly replace contact lenses daily)
  • Systemic health conditions known to alter tear film physiology
  • History of ocular surgery within the past 12 months
  • History of severe ocular trauma, active ocular infection, or inflammation
  • Currently using Accutane or eye medications
  • Pregnant or breast feeding

Sites / Locations

  • University of Alabama at Birmingham
  • Lindenhurst Eye Physicians & Surgeons, P.C.
  • Southern College of Optometry

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Systane Complete

No Treatment

Arm Description

Subjects randomized to this group will be asked to use Systane Complete once before and after contact lens use.

Subjects randomized to this group will not receive a treatment.

Outcomes

Primary Outcome Measures

Contact Lens Symptoms
Improvement in contact lens symptoms as measured with the Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) and CLDEQ-4 at 2 weeks compared to baseline. The CLDEQ-8 score range is 0 to 37 with 0 being the best score. Subjects were required to have a CLDEQ-8 of at least 12 in order to participate. The CLDEQ-4 is a subset of the CLDEQ-8, and it was also reported because it is a unidimensional measure of ocular discomfort in contact lens wearers. The CLDEQ-4 has a score range of 0 to 18 with 0 being the best score.

Secondary Outcome Measures

End of Day Eye Comfort
Improvement in eye symptoms as measured with the Standardized Patient Evaluation of Eye Dryness (SPEED) at 2 weeks compared to baseline. The scale range is 0 to 28 with 0 being the best score.
Corneal Staining
Improvement in conjuctivial staining at two weeks compared to baseline using the Brien Holden Vision Institute (BHVI) scale, which measures five regions of the eye on a (0-4) scale (max of 20 per metric). A score 0 is the best possible score.
Schirmer's I Test Without Anesthetic
Improvement in tear volume as measured in mm of wetting with a Schirmer's strip at 5 mins at 2 weeks compared to baseline. The score ranges is 0 mm to 35 mm with 35 mm being the best score.
Tear Break-Up Time (TBUT)
Improvement in tear break up time as measured with a slit-lamp biomicroscope and sodium fluorescein in seconds at 2 weeks compared to baseline. Scores range for 0 to 60 seconds with 60 seconds being the best score.

Full Information

First Posted
September 21, 2018
Last Updated
March 23, 2020
Sponsor
University of Alabama at Birmingham
Collaborators
Southern College of Optometry, Lindenhurst Eye Physicians & Surgeons, PC, Alcon Research
search

1. Study Identification

Unique Protocol Identification Number
NCT03682809
Brief Title
Evaluation of Systane Complete for the Treatment of Contact Lens Discomfort
Official Title
Evaluation of Systane Complete for the Treatment of Contact Lens Discomfort
Study Type
Interventional

2. Study Status

Record Verification Date
March 2020
Overall Recruitment Status
Completed
Study Start Date
November 19, 2018 (Actual)
Primary Completion Date
March 23, 2019 (Actual)
Study Completion Date
March 23, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Alabama at Birmingham
Collaborators
Southern College of Optometry, Lindenhurst Eye Physicians & Surgeons, PC, Alcon Research

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Clinicians commonly use artificial tears off label for treating contact lens (CL) discomfort and the dry eye associated with CLs because new artificial tear formulations have the potential to outperform the available CL rewetting drops. While off-label, McDonald et al. have previously shown that using a common artificial tear, Systane Ultra, before and after CL use is an effective means for treating daily disposable CL wears who have CL discomfort. Recently, a new formulation of artificial tears, Systane Complete, was released to the market. Systane Complete is a unique formulation that has combined elements from both Systane Ultra (indicated for aqueous deficient dry eye) and Systane Balance (indicated for evaporative dry eye) to create an artificial tear with an indication for aqueous deficient, evaporative, and mixed (both aqueous deficient and evaporative) dry eye. Thus, the goal of this study is to determine in a randomized clinical trial if Systane Complete is able to effectively improve the symptoms of patients who have CL discomfort.
Detailed Description
Soft contact lenses (CL) are the most common CL modality with over 140 million users world. Despite many improvements in CL materials and solutions, the advent of daily disposable CLs, and the addition of rewetting drops to improve CL comfort, research has shown that between 21% to 64% of CL wearers permanently discontinue CL use because of eye discomfort. Contact Lens Discomfort (CLD) as defined by the Tear Film and Ocular Surface Society (TFOS) "is a condition characterized by episodic or persistent adverse ocular sensations related to lens wear, either with or without visual disturbance, resulting from reduced compatibility between the CL and the eye's environment, which can lead to decreased wearing time and discontinuation of CL wear." TFOS further states that CLD is a multifactorial condition that stems from both CL (e.g., material design, fit, care system) and environmental factors (patient factors, medication compliance, external environmental factors, ocular environment). While environmental factors related to the patient such as age and sex are inherent, rewetting drops or artificial tears can be used to treat tear film deficiencies associated with CLD. The U.S. Food & Drug Administration (FDA) defines rewetting/lubricating drops as "an in-eye solution for use with CLs" that contains "one or more active ingredients (e.g., ophthalmic demulcents) in sufficient concentration to alleviate symptoms of discomfort from CL wear by physical means." Clinicians also commonly use artificial tears off label for treating CLD and the dry eye associated with CLs because artificial tear formulations have the potential to outperform CL rewetting drops. The FDA separately classifies artificial tears as topical drops that contain specific types of demulcents or emollients. While off-label, McDonald et al. have previously shown that using a common artificial tear, Systane Ultra, before and after CL use is an effective means for treating daily disposable CL wears who have CLD. Recently, a new formulation of artificial tears, Systane Complete, was released to the market. Systane Complete is a unique formulation that has combined elements from both Systane Ultra (indicated for aqueous deficient dry eye) and Systane Balance (indicated for evaporative dry eye) to create an artificial tear with an indication for aqueous deficient, evaporative, and mixed (both aqueous deficient and evaporative) dry eye. Thus, the Research Goal of this study is to determine in a randomized clinical trial if Systane Complete is able to effectively improve the symptoms of CLD suffers.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Contact Lens Discomfort, Dry Eye
Keywords
Artificial Tears, Systane Complete, Contact Lens Discomfort, Dry Eye, Daily Disposable Contact Lenses

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
One group will be randomized Systane Complete, and one group will be randomized to no treatment.
Masking
ParticipantInvestigator
Masking Description
The patients who are randomized to Systane Complete will be masked to the brand of the artificial tears. There will be a masked examiner who does not know the subject's study group.
Allocation
Randomized
Enrollment
46 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Systane Complete
Arm Type
Experimental
Arm Description
Subjects randomized to this group will be asked to use Systane Complete once before and after contact lens use.
Arm Title
No Treatment
Arm Type
No Intervention
Arm Description
Subjects randomized to this group will not receive a treatment.
Intervention Type
Drug
Intervention Name(s)
Systane Complete
Intervention Description
Systane Complete is an artificial tear indicated for patients who have evaporative, aqueous deficient, or mixed dry eye.
Primary Outcome Measure Information:
Title
Contact Lens Symptoms
Description
Improvement in contact lens symptoms as measured with the Contact Lens Dry Eye Questionnaire-8 (CLDEQ-8) and CLDEQ-4 at 2 weeks compared to baseline. The CLDEQ-8 score range is 0 to 37 with 0 being the best score. Subjects were required to have a CLDEQ-8 of at least 12 in order to participate. The CLDEQ-4 is a subset of the CLDEQ-8, and it was also reported because it is a unidimensional measure of ocular discomfort in contact lens wearers. The CLDEQ-4 has a score range of 0 to 18 with 0 being the best score.
Time Frame
Baseline through 2 Weeks
Secondary Outcome Measure Information:
Title
End of Day Eye Comfort
Description
Improvement in eye symptoms as measured with the Standardized Patient Evaluation of Eye Dryness (SPEED) at 2 weeks compared to baseline. The scale range is 0 to 28 with 0 being the best score.
Time Frame
Baseline through 2 Weeks
Title
Corneal Staining
Description
Improvement in conjuctivial staining at two weeks compared to baseline using the Brien Holden Vision Institute (BHVI) scale, which measures five regions of the eye on a (0-4) scale (max of 20 per metric). A score 0 is the best possible score.
Time Frame
Baseline through 2 Weeks
Title
Schirmer's I Test Without Anesthetic
Description
Improvement in tear volume as measured in mm of wetting with a Schirmer's strip at 5 mins at 2 weeks compared to baseline. The score ranges is 0 mm to 35 mm with 35 mm being the best score.
Time Frame
Baseline through 2 Weeks
Title
Tear Break-Up Time (TBUT)
Description
Improvement in tear break up time as measured with a slit-lamp biomicroscope and sodium fluorescein in seconds at 2 weeks compared to baseline. Scores range for 0 to 60 seconds with 60 seconds being the best score.
Time Frame
Baseline through 2 Weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Self-reported contact lens discomfort Contact Lens Dry Eye Questionnaire (CLDEQ)-8 scores ≥ 12 Daily disposable contact lens wearer Best-corrected visual acuity of 20/30 or better Exclusion Criteria: All other contact lens types (e.g., currently wearing two week or monthly replacement contact lenses or hard contact lenses) Non-compliant daily disposable contact lens wearers (must regularly replace contact lenses daily) Systemic health conditions known to alter tear film physiology History of ocular surgery within the past 12 months History of severe ocular trauma, active ocular infection, or inflammation Currently using Accutane or eye medications Pregnant or breast feeding
Facility Information:
Facility Name
University of Alabama at Birmingham
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35294
Country
United States
Facility Name
Lindenhurst Eye Physicians & Surgeons, P.C.
City
Babylon
State/Province
New York
ZIP/Postal Code
11702
Country
United States
Facility Name
Southern College of Optometry
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38104
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No
IPD Sharing Plan Description
There are no plans to share individual subject's data. Data will only be published in aggregate form.
Citations:
PubMed Identifier
24552755
Citation
McDonald M, Schachet JL, Lievens CW, Kern JR. Systane(R) ultra lubricant eye drops for treatment of contact lens-related dryness. Eye Contact Lens. 2014 Mar;40(2):106-10. doi: 10.1097/ICL.0000000000000018.
Results Reference
background

Learn more about this trial

Evaluation of Systane Complete for the Treatment of Contact Lens Discomfort

We'll reach out to this number within 24 hrs